<DOC>
	<DOCNO>NCT00168831</DOCNO>
	<brief_summary>To evaluate long term effect treatment two dos Tiotropium deliver Respimat inhaler patient COPD .</brief_summary>
	<brief_title>Tiotropium / Respimat One-Year Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Criteria Patients stable moderate severe COPD smoke history least 10 pack year eligible inclusion study . Patients significant disease COPD exclude patient recent history myocardial infarction , history malignancy , unstable lifethreatening cardiac arrhythmia , narrowangle glaucoma , asthma allergic condition . Patients treat cromolyn , nedocromil , oral betaadrenergics unstable dos oral corticosteroid ineligible inclusion study patient receive previous treatment tiotropium .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>